Zoetis (ZTS) came out with quarterly earnings of $1.58 per share, beating the Zacks Consensus Estimate of $1.46 per share. This compares to earnings of $1.36 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 8.22%. A quarter ago, it was expected that this animal health company would post earnings of $1.49 per share when it actually produced earnings of $1.56, delivering a surprise of 4.70%. Over the last four quarters, the compa ...

EXHIBIT 99.1 Zoetis Announces Third Quarter 2024 Results • Reports Revenue of $2.4 Billion, Growing 11%, and Net Income of $682 Million, or $1.50 per Diluted Share, Increasing 14% and 16%, Respectively, on a Reported Basis for Third Quarter 2024 • Delivers 14% Operational Growth in Revenue and 15% Operational Growth in Adjusted Net Income for Third Quarter 2024 • Reports Adjusted Net Income of $716 Million, or Adjusted Diluted EPS of $1.58, for Third Quarter 2024 • Raises Full Year 2024 Revenue Guidance to ...

Wall Street analysts forecast that Zoetis (ZTS) will report quarterly earnings of $1.46 per share in its upcoming release, pointing to a year-over-year increase of 7.4%. It is anticipated that revenues will amount to $2.29 billion, exhibiting an increase of 6.3% compared to the year-ago quarter. The consensus EPS estimate for the quarter has been revised 0.1% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estima ...

Core Viewpoint - Zoetis, Inc. is anticipated to exceed revenue and earnings estimates for Q3 2024, with revenues expected at $2.29 billion and earnings at $1.46 per share, as reported on November 4 [1][10]. Revenue Breakdown - The company generates most of its revenue from a diverse portfolio of veterinary medicines and vaccines for livestock and companion animals, with additional revenue from non-pharmaceutical categories like nutritional products and precision animal health services [2]. - In the United States segment, revenues are projected to rise to $1.27 billion, driven by increased sales of companion animal products, while the model estimate is slightly lower at $1.24 billion [3]. - The International segment is also expected to see revenue growth, estimated at $996.4 million, with the model estimate at $1.02 billion, primarily due to higher sales of companion animal products [4]. Product Performance - Sales of companion animal products, particularly monoclonal antibodies for osteoarthritis pain (Librela for dogs and Solensia for cats) and the Simparica Trio flea, tick, and heartworm product, are expected to significantly contribute to revenue growth in both segments [4][5]. - Key dermatology products like Apoquel and Cytopoint are also anticipated to support growth in these segments [5]. - The FDA's approval of Apoquel Chewable tablets for allergic dermatitis in dogs is expected to boost sales in the upcoming quarter [6]. Livestock Products - Livestock product sales in the United States are likely to increase, driven by higher sales of cattle and swine products, while the International segment is expected to see growth in cattle and poultry portfolios due to price increases [7]. Earnings Surprise History - Zoetis has a positive earnings surprise history, surpassing estimates in three of the last four quarters, with an average surprise of 0.42% [8]. Earnings Prediction - The company has an Earnings ESP of +0.69%, indicating a likelihood of an earnings beat, with the most accurate estimate at $1.47 per share [10].

It is always good to have some companies in your portfolio that have an anticyclical nature. Companies that are less sensitive to fluctuations in the economy, allowing the compounding effect to work undisturbed.I am a Dutch manual therapist (MSc) and a passionate retail investor. My investment journey started in 2021 and from that point my love for investing has begun. Nearly from the start i had a strong preference for dividend growth investing.My investment goal is to retire early with the dividend growth ...

Join iREIT on Alpha today to get the most in-depth research that includes REITs, mREITs, Preferreds, BDCs, MLPs, ETFs, and other income alternatives. 438 testimonials and most are 5 stars. Nothing to lose with our FREE 2-week trial . I make many mistakes. However, remaining bullish on Zoetis Inc. (NYSE: ZTS ) in April wasn't one of them. Back then, the veterinarian healthcare stock cratered due to headlines about potential risks associated with one of its blockbuster Analyst's Disclosure: I/we have no stock ...

Shares of Zoetis (ZTS) have risen 15.4% in the past three months compared with the industry’s 9.3% growth. The stock has also outperformed the sector as well as the S&P 500 as seen in the chart below. The stock is also trading above both its 50 and 200-day moving averages from early August.ZTS Stock Outperforms Industry, Sector & S&P 500    Image Source: Zacks Investment ResearchZoetis is a major player in the animal health market. The company operates in eight major product categories: vaccines, anti-infec ...

Zoetis (ZTS) closed at $191.09 in the latest trading session, marking a +0.2% move from the prior day. The stock's change was less than the S&P 500's daily gain of 0.54%. Elsewhere, the Dow saw an upswing of 0.72%, while the tech-heavy Nasdaq appreciated by 0.65%. Shares of the animal health company witnessed a gain of 3.6% over the previous month, trailing the performance of the Medical sector with its gain of 4.37% and the S&P 500's gain of 4.86%. The investment community will be closely monitoring the pe ...

It has been about a month since the last earnings report for Zoetis (ZTS) . Shares have added about 1.4% in that time frame, underperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Zoetis due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. Zoetis Q2 Earnings & Revenues Beat, ’24 Outlook RaisedZo ...

Zoetis Inc (NYSE:ZTS) Morgan Stanley 22nd Annual Global Healthcare Conference September 4, 2024 1:05 PM ET Company Participants Kristin Peck - Chief Executive Officer Wetteny Joseph - Chief Financial Officer Conference Call Participants Erin Wright - Morgan Stanley Erin Wright Thanks, and good afternoon, everyone. Welcome to the Morgan Stanley Healthcare Conference. I'm Erin Wright, Lead Healthcare Services Analyst at Morgan Stanley. We're happy to have with us today, Zoetis' CEO, Kristin Peck with us; as ...